Skyrizi (Risankizumab)

Skyrizi (risankizumab) is used by adults with moderate to severe plaque psoriasis.  Skyrizi stops the protein IL 23, which is associated with inflammation.  For this reason, Skyrizi reduces inflammation, itching, burning, scaling, pain and redness.

Skyrizi is given subcutaneously as 150 mg (two 75 mg injections) by subcutaneous injection at week 0, week 4, and every 12 weeks thereafter.  If no response is there after 16 weeks of treatment, treatment may be discontinued.  Often improvement will come after 16 weeks if there is some initial response to Skyrizi.

This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.